<DOC>
	<DOC>NCT00859053</DOC>
	<brief_summary>The purpose of this study is to assess the effects of hepatic impairment on the single dose pharmacokinetics of BMS-790052.</brief_summary>
	<brief_title>Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Key Male and female subjects aged 18 to 70 years, with hepatic impairment conforming to ChildPugh class A, B or C Healthy subjects to the extent possible matched to the first four hepatically impaired subject in each ChildPugh class with regard to age (approximately ± 10 years), body weight (approximately ± 20%) and gender Key History of esophageal and gastric variceal bleeding within past 6 months Primarily cholestatic liver diseases Active alcoholic hepatitis Stable encephalopathy of &gt;= Stage 2 Presence of severe ascites or edema Presence of hepatopulmonary or hepatorenal syndrome Positive for HCV, unless HCV RNA is undetectable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>